Oral anticoagulant drugs: pharmacokinetic aspects.

No abstract is available for this paper.

• Publication year

  1978

• Venue

  Seminars in hematology (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 341326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect

  1976cited by this paper
• Oral anticoagulants--the totem and the taboo.

  1976cited by this paper
• Intrasubject variation of warfarin binding to protein in serum of patients with cardiovascular disease

  1976cited by this paper
• An NADPH dependent warfarin reductase in human and rat liver and kidney soluble fraction.

  1975cited by this paper
• Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

  1974cited by this paper
• Letter: Effect of plasma protein binding on elimination of warfarin.

  1974cited by this paper
• Dose‐dependent enzyme induction

  1973cited by this paper
• Kinetics of warfarin absorption in man

  1973cited by this paper
• Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols.

  1973cited by this paper
• The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats.

  1972cited by this paper
• Vitamin K in hereditary resistance to oral anticoagulant drugs.

  1971cited by this paper
• Determinants of the response to oral anticoagulant drugs in man.

  1970cited by this paper
• Intoxication with Phenprocoumon (Marcoumar) Pharmacokinetics and Side Effects

  1969cited by this paper
• Effect of heptabarbital on the response to bishydroxycoumarin in man.

  1969cited by this paper
• Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin

  1969cited by this paper
• Interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin.

  1969cited by this paper
• Change in receptor site affinity: A proposed explanation for the potentiating effect of D‐thyroxine on the anticoagulant response to warfarin

  1967cited by this paper
• Dose response and minimal daily requirement for vitamin K in man.

  1967cited by this paper
• Coumarin anticoagulant drugs: hereditary resistance in man.

  1965cited by this paper
• Human sources and absorption of vitamin K in relation to anticoagulation stability.

  1965cited by this paper
• Studies on the Coumarin Anticoagulant Drugs : A Comparison of the Pharmacodynamics of Dicumarol and Warfarin in Man

  1964cited by this paper
• HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED.

  1964cited by this paper
• STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN.

  1963cited by this paper
• Effect of sodium dextrothyroxine in patients receiving anticoagulants.

  1962cited by this paper
• Dangers of prolonged anticoagulant therapy in hepatic disease. Diathesis and intercurrent acute hepatitis.

  1960cited by this paper
• High Serum Transaminase Activity in Heart Disease: Circulatory Failure and Hepatic Necrosis

  1960cited by this paper
• The effect of thyroid function on the prothrombin time response to warfarin in rats

  1957cited by this paper
• The physiologic disposition of phenylindanedione in man.

  1954cited by this paper
• The physiological disposition of ethyl biscoumacetate (tromexan) in man and a method for its estimation in biological material.

  1952cited by this paper
• Experimentally induced changes in the prothrombin level of the blood; prothrombin concentration of new-born pups of a mother given dicumarol before parturition.

  1946cited by this paper
• INFLUENCE OF FEVER UPON THE ACTION OF 3,3'-METHYLENE-BIS-(4-HYDROXYCOUMARIN) (DICUMAROL).

  1943cited by this paper

• Anticoagulants: From chance discovery to structure-based design.

  2025cites this paper
• A Historical Perspective on the Reversal of Anticoagulants.

  2022cites this paper
• A facile synthesis of some novel thiazoles, arylazothiazoles, and pyrazole linked to thiazolyl coumarin as antibacterial agents

  2020cites this paper
• Knowledge, Adherence, and Quality of Life among Warfarin Therapy Users

  2019cites this paper
• Pharmacology of Oral Anticoagulants

  2019cites this paper
• Effects of CYP2C11 gene knockout on the pharmacokinetics and pharmacodynamics of warfarin in rats

  2019cites this paper
• Transitioning Between Anticoagulants

  2018cites this paper
• Anticoagulant Reversal and Anesthetic Considerations.

  2017cites this paper
• Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study

  2017influential citation
• The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)

  2017influential citation
• Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies.

  2017cites this paper
• Ezetimibe enhances and stabilizes anticoagulant effect of warfarin

  2016cites this paper
• Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome

  2016cites this paper
• Self-monitoring and self-management of oral anticoagulation.

  2016cites this paper
• Peri-procedural management of patients taking oral anticoagulants

  2015cites this paper
• Oral Anticoagulants and Status of Antidotes for the Reversal of Bleeding Risk

  2015cites this paper
• The effect of VKORC1 (-1639 G>A) gene polymorphism and its related clotting factor IIa and Xa on warfarin therapy in patients with atrial fibrillation: a multi-ethnic Sarawak population study

  2015cites this paper
• Anticoagulant therapy in pregnant patients with metabolic syndrome: a review.

  2014cites this paper
• Warfarin Interactions with Medicinal Herbs

  2014cites this paper
• Novel Oral Anticoagulants in Cardiovascular Disease

  2014cites this paper
• VKORC1 and CYP2C9 genotype distribution in Asian countries.

  2014cites this paper
• Antithrombotic therapy and thrombolysis: the present and the future

  2014cites this paper
• Polskie zalecenia dotyczące leczenia antagonistami witaminy K

  2013cites this paper
• Warfarin Therapy American Heart Association/American College of Cardiology Foundation Guide to

  2013cites this paper
• Caracterización biológica y clínica del riesgo trombótico y hemorrágico de pacientes con fibrilación auricular no valvular bajo tratamiento anticoagulante oral.

  2013cites this paper
• Warfarin and acetaminophen interaction Assessment to establish its clinical relevance

  2013cites this paper
• Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation

  2013cites this paper
• Conventional and new oral anticoagulants in the treatment of chest disease and its complications.

  2013cites this paper
• Changes to prothrombin international normalized ratio in patients receiving hemodialysis.

  2013cites this paper
• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• Determinants of adverse events during oral anticoagulant treatment

  2012cites this paper
• Enquête sur la qualité du suivi ambulatoire des anticoagulantsoraux chez les patients de plus de 75 ans

  2012cites this paper
• Stroke Prevention in Atrial Fibrillation: Where are We Now?

  2012cites this paper
• International Normalized Ratio Decreases After Hemodialysis Treatment in Patients Treated With Warfarin

  2012cites this paper
• Anticoagulation for Non‐Valvular Atrial Fibrillation in Older People

  2012cites this paper
• Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know

  2011cites this paper
• Cincuenta años de uso clínico de la warfarina

  2010cites this paper
• Cincuenta años de uso clínico de la warfarina

  2010cites this paper
• Topical issues in venous thromboembolism.

  2010cites this paper
• [Fifty years of clinical use of warfarin].

  2010cites this paper
• Topical Issues in Venous Thromboembolism

  2010cites this paper
• Blood Coagulation, Fibrinolysis and Cellular Haemostasis Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin

  2010cites this paper
• Gastrointestinal absorption of heparins

  2009cites this paper
• Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin

  2008cites this paper
• Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.

  2008cites this paper
• Clinical factors influencing the sensitivity to warfarin when restarted after surgery

  2008cites this paper
• Practice Guidelines (8th Edition) Chest Physicians Evidence-Based Clinical Vitamin K Antagonists: American College of Pharmacology and Management of the

  2008cites this paper
• Vitamin K Antagonists and Novel Oral Anticoagulant

  2007cites this paper
• Conventional and near-patient tests of coagulation

  2007cites this paper
• How anticoagulants work

  2006cites this paper
• Drug interaction between capecitabine and warfarin: a case report and review of the literature.

  2006cites this paper
• Agents Used for Anticoagulation

  2005cites this paper
• Interaction of Antibiotics and Warfarin in Pediatric Cardiology Patients

  2005cites this paper
• The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• Avoidance of Bleeding During Surgery in Patients Receiving Anticoagulant and/or Antiplatelet Therapy

  2004cites this paper
• Recent advances in the discovery and development of direct coagulation factor Xa inhibitors.

  2003cites this paper
• American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

  2003cites this paper
• American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

  2003cites this paper
• Plasma levels of endothelial protein C receptor respond to anticoagulant treatment.

  2002cites this paper
• Pharmacokinetic study of FFP photochemically treated with amotosalen (S‐59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin

  2002cites this paper
• Oral Anticoagulation Thresholds

  2001cites this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cites this paper
• Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range

  2001cites this paper
• RELATIVE IMPACT OF VARIOUS SOURCES OF PHARMACOKINETIC AND PHARMACODYNAMIC VARIABILITY ON WARFARIN RESPONSE

  2000cites this paper
• Ciprofloxacin–warfarin coagulopathy: A case series

  2000cites this paper
• Probable Antagonism of Warfarin by Green Tea

  1999cites this paper
• Evaluation of protein C and protein S levels during oral anticoagulant therapy.

  1998cites this paper
• Interaction between Fenofibrate and Warfarin

  1998cites this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  1998cites this paper
• Accuracy of repeated blood sampling in rats: a new technique applied in pharmacokinetic/pharmacodynamic studies of the interaction between warfarin and co-enzyme Q10.

  1998cites this paper
• Monitoring Chronic Oral Anticoagulant Therapy

  1997cites this paper
• Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis

  1997cites this paper
• The characterization of potent novel warfarin analogs.

  1997cites this paper
• Warfarin Withdrawal

  1996cites this paper
• Antithrombotic, anticoagulant, and thrombolytic agents.

  1996cites this paper
• -Anticoagulant drugs-.

  1996cites this paper
• Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor.

  1995cites this paper
• Anticoagulation/platelet inhibition for atrial fibrillation.

  1995cites this paper
• Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.

  1995cites this paper
• Oral anticoagulation: improving the risk-benefit ratio.

  1995cites this paper
• Warfarin-induced changes in procoagulant and anticoagulant proteins.

  1995cites this paper
• Interactions of Warfarin with Drugs and Food

  1994cites this paper
• Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association.

  1994cites this paper
• Oral anticoagulant therapy--50 years later.

  1993cites this paper
• Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.

  1992cites this paper
• Oral anticoagulant drugs.

  1991cites this paper
• Thrombosis and Cerebrovascular Disease

  1987cites this paper
• New Trends in Diagnosis and Management of Stroke

  1987cites this paper
• Kinetics of bromadiolone, anticoagulant rodenticide, in the Norway rat (Rattus norvegicus).

  1987cites this paper
• Mechanism of Action and Monitoring of Anticoagulants

  1986cites this paper
• [Anticoagulant therapy with antivitamins K].

  1984cites this paper
• Combining NSAIDs with anticoagulants: yes and no.

  1984cites this paper
• Potentiation of Oral Anticoagulant Effect by L-thyroxine

  1984cites this paper
• Oral anticoagulant therapy.

  1983cites this paper
• Variability in the human drug response.

  1983cites this paper
• Trauma and oral anticoagulants.

  1983cites this paper
• Panel conference. Antithrombotic therapy of artificial organs.

  1981cites this paper
• Predictability of the warfarin maintenance dosage based on the initial response.

  1981cites this paper
• Bleeding associated with antithrombotic therapy.

  1980cites this paper